International Edition
Latest News
Health

Daraxonrasib Nearly Doubles Survival in Treated Pancreatic Cancer, Italian Access Under Review

Daraxonrasib nearly doubled median overall survival to 13.2 months versus 6.7 months with physician-choice chemotherapy in previously treated metastatic pancreatic adenocarcinoma, the RASolute 302 trial found. The phase 3 study, published July 23 in the New England Journal…

Daraxonrasib Nearly Doubles Survival in Treated Pancreatic Cancer, Italian Access Under Review

Daraxonrasib nearly doubled median overall survival to 13.2 months versus 6.7 months with physician-choice chemotherapy in previously treated metastatic pancreatic adenocarcinoma, the RASolute 302 trial found.

The phase 3 study, published July 23 in the New England Journal of Medicine, randomized 500 patients whose disease had progressed after one prior systemic therapy. Median progression-free survival reached 7.2 months with the oral RAS inhibitor compared with 3.6 months with chemotherapy, according to the investigators led by Eileen M. O’Reilly of Memorial Sloan Kettering Cancer Center.

“Disporre oggi di farmaci in grado di colpire la proteina RAS rappresenta uno dei più importanti successi della ricerca oncologica degli ultimi decenni,” said Alfredo Budillon, scientific director of the Istituto Nazionale Tumori Fondazione Pascale in Naples, speaking at a World Pancreatic Cancer Day forum at the institute on November 19. “La ricerca clinica, tuttavia, non si ferma qui.”

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for daraxonrasib, to be marketed as Rasonque, on October 15 for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. Agenzia Italiana del Farmaco announced on November 18 it had begun a rolling assessment of pricing and reimbursement data with the stated goal of shortening timelines without losing rigor, mondosanita.it reported. Eleven patient associations have asked the health ministry for a national technical table and free provision of the drug pending national reimbursement. The Italian Association of Medical Oncology, through president Massimo Di Maio, called for a rapid conclusion of negotiations between AIFA and the manufacturer, warning that therapeutic innovation must be accessible regardless of region or income. Lombardy recently authorized the purchase of daraxonrasib from the United States for a single patient, illustrating the patchwork access that can emerge before national reimbursement is settled, ilmattino.it reported.

The RASolute 302 trial enrolled patients with KRAS G12 mutations, which accounted for 91.8 percent of the study population. Grade 3 or higher adverse events occurred in 61.8 percent of patients receiving daraxonrasib and 69.6 percent of those receiving chemotherapy. Current first-line options for fit patients with metastatic disease include FOLFIRINOX, its modified versions, NALIRIFOX — which entered standard practice after the NAPOLI 3 trial — and gemcitabine plus nab-paclitaxel. For patients with germline BRCA1 or BRCA2 mutations, maintenance olaparib after at least four months of platinum-based chemotherapy improved median progression-free survival to 7.4 months versus 3.8 months with placebo in the POLO trial, though overall survival benefit was not statistically significant. An estimated 14,270 new pancreatic cancer cases were diagnosed in Italy in 2025, according to figures cited by the Pascale institute. Only about one in five patients presents with resectable disease at diagnosis.

Symptoms such as persistent upper abdominal or back pain, unexplained weight loss, jaundice, and new-onset diabetes in adulthood warrant timely clinical evaluation. Multidisciplinary discussion involving surgeons, medical oncologists, radiologists, endoscopists, and pathologists remains the standard for treatment planning across all stages. Molecular profiling at diagnosis — including testing for KRAS, BRCA, microsatellite instability, and rare fusions — can direct patients to targeted therapies or clinical trials earlier in the course of disease.

Stroma-modifying strategies and oncolytic viruses are also under investigation to improve drug delivery in the dense pancreatic microenvironment.

“The months gained in a trial have value only if the real-world pathway allows the patient to receive the treatment,” Budillon said at the November 19 forum. AIFA’s rolling review continues; a final reimbursement decision date has not been announced.

About the author: Health Desk

Health Desk at Archynewsy.